Echo IQ’s heart failure AI, validated on approximately 17,000 Mayo Clinic echocardiogram studies with 99.5% sensitivity and 91% specificity, is now being evaluated in cancer patients to see if it can predict treatment-related heart failure risk earlier. The Mayo Clinic Arizona collaboration is designed to generate predictive risk scores from de-identified echocardiographic data, with a peer-reviewed paper planned after study completion in the first half of 2027.

Why It Matters To Oncology

• As cancer survival improves, more patients live long enough to face cardiotoxic effects from therapy, increasing the need for earlier cardiovascular risk stratification.

• With more than 20 million new cancer cases diagnosed each year, cardiac monitoring during treatment is a growing operational and clinical burden.

• If the model performs in oncology, it could help clinicians identify heart failure risk before symptoms emerge and potentially inform treatment decisions.

The Financials

• Echo IQ said it submitted EchoSolv HF to the FDA late last year as a heart failure clinical decision support tool.

• The submission was backed by an independent validation dataset of about 17,000 echos from the Mayo Clinic Platform.

• The company already has FDA clearance, received in 2024, for its AI platform in aortic stenosis and has deployed it at systems including Beth Israel Deaconess and Mount Sinai.

What They're Saying

• CEO Dustin Haines said the Mayo partnership is “an important opportunity to evaluate the company's cardiac AI platform in a high-need clinical population, where earlier identification of cardiovascular risk may inform clinical decision making.”

• The company is positioning cardiotoxicity as a major unmet need at the intersection of oncology and heart disease.

What's Next

• The Mayo Clinic Arizona study will test whether the AI can generate predictive heart failure risk scores in an oncology population using de-identified echo data.

• Partners plan to publish a peer-reviewed paper after the study concludes in the first half of 2027.

• Key watchpoint for clinicians and drug developers: whether strong retrospective validation in general echo datasets translates into actionable performance in cancer care.